Rhumbline Advisers Lowers Holdings in ICU Medical, Inc. $ICUI

Key Points

• Rhumbline Advisers has reduced its stake in ICU Medical, Inc. by 4.5%, now holding 64,822 shares valued at approximately $9 million.
• Institutional investors own a significant majority, 96.10%, of ICU Medical's stock, reflecting strong interest from large financial firms.
• ICU Medical reported an earnings per share of $2.10 for the last quarter, surpassing expectations and illustrating resilience despite an 8% revenue decline year-over-year.

Rhumbline Advisers cut its holdings in shares of ICU Medical, Inc. (NASDAQ:ICUI - Free Report) by 4.5% in the first quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 64,822 shares of the medical instruments supplier's stock after selling 3,069 shares during the quarter. Rhumbline Advisers owned 0.26% of ICU Medical worth $9,001,000 at the end of the most recent reporting period.

A number of other institutional investors also recently bought and sold shares of the business. Xponance Inc. raised its position in ICU Medical by 5.3% during the 1st quarter. Xponance Inc. now owns 1,714 shares of the medical instruments supplier's stock worth $238,000 after buying an additional 86 shares during the last quarter. Blue Trust Inc. raised its position in ICU Medical by 23.0% during the 1st quarter. Blue Trust Inc. now owns 801 shares of the medical instruments supplier's stock worth $111,000 after buying an additional 150 shares during the last quarter. GAMMA Investing LLC raised its position in ICU Medical by 27.2% during the 1st quarter. GAMMA Investing LLC now owns 716 shares of the medical instruments supplier's stock worth $99,000 after buying an additional 153 shares during the last quarter. Vise Technologies Inc. raised its position in ICU Medical by 7.1% during the 4th quarter. Vise Technologies Inc. now owns 2,649 shares of the medical instruments supplier's stock worth $411,000 after buying an additional 176 shares during the last quarter. Finally, AQR Capital Management LLC raised its position in ICU Medical by 2.5% during the 1st quarter. AQR Capital Management LLC now owns 9,360 shares of the medical instruments supplier's stock worth $1,297,000 after buying an additional 229 shares during the last quarter. 96.10% of the stock is owned by hedge funds and other institutional investors.

ICU Medical Trading Down 2.2%

ICUI traded down $2.86 on Tuesday, hitting $129.32. The company had a trading volume of 147,126 shares, compared to its average volume of 268,020. The firm has a market cap of $3.19 billion, a P/E ratio of -85.02 and a beta of 0.86. ICU Medical, Inc. has a 1 year low of $107.00 and a 1 year high of $196.26. The company's fifty day moving average price is $126.27 and its 200 day moving average price is $133.50. The company has a current ratio of 2.44, a quick ratio of 1.17 and a debt-to-equity ratio of 0.63.

ICU Medical (NASDAQ:ICUI - Get Free Report) last issued its quarterly earnings data on Thursday, August 7th. The medical instruments supplier reported $2.10 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.44 by $0.66. The firm had revenue of $543.57 million for the quarter, compared to analyst estimates of $543.33 million. ICU Medical had a negative net margin of 1.56% and a positive return on equity of 7.24%. ICU Medical's revenue was down 8.0% on a year-over-year basis. During the same period in the previous year, the firm earned $1.56 EPS. ICU Medical has set its FY 2025 guidance at 6.850-7.15 EPS. As a group, equities analysts expect that ICU Medical, Inc. will post 4.11 earnings per share for the current year.

Insider Activity

In related news, Director David C. Greenberg acquired 1,200 shares of ICU Medical stock in a transaction that occurred on Wednesday, August 27th. The shares were purchased at an average cost of $126.42 per share, for a total transaction of $151,704.00. Following the acquisition, the director owned 7,960 shares in the company, valued at approximately $1,006,303.20. This represents a 17.75% increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, CEO Vivek Jain purchased 21,929 shares of the business's stock in a transaction on Thursday, August 14th. The shares were acquired at an average price of $112.84 per share, for a total transaction of $2,474,468.36. Following the completion of the purchase, the chief executive officer directly owned 130,149 shares of the company's stock, valued at approximately $14,686,013.16. This trade represents a 20.26% increase in their ownership of the stock. The disclosure for this purchase can be found here. 1.50% of the stock is currently owned by insiders.

Wall Street Analyst Weigh In

A number of equities research analysts have recently commented on the stock. Wall Street Zen raised shares of ICU Medical from a "hold" rating to a "buy" rating in a research note on Friday, September 5th. Piper Sandler lifted their price target on shares of ICU Medical from $145.00 to $153.00 and gave the company an "overweight" rating in a research note on Wednesday, September 10th. Finally, Raymond James Financial dropped their price target on shares of ICU Medical from $187.00 to $180.00 and set a "strong-buy" rating on the stock in a research note on Friday, August 8th. One investment analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating and one has given a Hold rating to the company. According to data from MarketBeat, the stock has a consensus rating of "Buy" and a consensus target price of $181.00.

ICU Medical Profile

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.